Homemarket News

Dabur and Gland Pharma: Thursday's top brokerage calls

Dabur and Gland Pharma: Thursday's top brokerage calls

Dabur and Gland Pharma: Thursday's top brokerage calls
Read Time
1 Min(s) Read
Profile image

By Sangam Singh  Oct 27, 2022 8:45:23 AM IST (Updated)

Morgan Stanley has an 'overweight' call on Gland Pharma with a target price of Rs 2,748 on its shares while Goldman Sachs has a 'buy' call on Dabur with a target price of Rs 680 on its shares.

Gland Pharma |

Recommended Articles

View All
Morgan Stanley has an 'overweight' call on Gland Pharma with a target price of Rs 2,748 on its shares. According to the brokerage house, the company reported a good recovery in its sales, but the margin looks disappointing.

Gland Pharma | CITI has a 'sell' call on Gland Pharma with a target price of Rs 1,920 on its shares. According to the brokerage house, the company reported decline in its margin due to increased competition.
Dabur India | Morgan Stanley has an 'equal-weight' call on Dabur with a target price of Rs 537 on its shares. According to the brokerage house, the company's second quarter earning are largely in-line with expectations. The brokerage also added that company's growth in rural areas and healthcare segment is weak.
Dabur India | Goldman Sachs has a 'buy' call on Dabur with a target price of Rs 680 on its shares. According to the brokerage house, the company's acquisition of spices brand is a significant boost for its ambition, but weak rural demand is a key risk.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!